← Back to headlines
Gilead Sciences Q2 Sales Boosted by HIV and Oncology Growth
Gilead Sciences reported a 10% jump in Q2 base sales, driven by strong growth in its HIV and oncology segments, despite a decline in Veklury sales.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
August Manufacturing PMI Data Reveals Divergent Global Economic Performance
25m ago
Shein’s Hong Kong IPO Debut Underwhelms Amid Geopolitical Risks and New Fashion Levies
27m ago
Wall Street Futures Drop as Rising Yields and Oil Prices Weigh on Markets
41m ago
IKEA Launches €1.2 Billion Price Cut Campaign Across Europe
46m ago